Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
12:46pm, Thursday, 14'th Aug 2025
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
04:00pm, Wednesday, 13'th Aug 2025
PALO ALTO, Calif. , Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025.
Kodiak Sciences to Host Investor R&D Day on July 16, 2025
08:00am, Thursday, 10'th Jul 2025
PALO ALTO, Calif. , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing t
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
04:45pm, Wednesday, 25'th Jun 2025
PALO ALTO, Calif. , June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
12:31pm, Friday, 13'th Jun 2025
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
09:32pm, Thursday, 29'th May 2025
PALO ALTO, Calif. , May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
12:06pm, Thursday, 15'th May 2025
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
04:15pm, Wednesday, 14'th May 2025
PALO ALTO, Calif. , May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025.
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
11:43pm, Thursday, 01'st May 2025
PALO ALTO, Calif. , May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)
10:35am, Tuesday, 01'st Apr 2025
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
10:46am, Friday, 28'th Mar 2025
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Thursday, 27'th Mar 2025
PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended Decemb
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
04:39pm, Monday, 10'th Mar 2025
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high s
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
08:08pm, Sunday, 23'rd Feb 2025
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO,
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
07:30am, Tuesday, 04'th Feb 2025
PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
